Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Study acronym: MO-TRANS
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 69 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Study sites: 110 to 111v69
  2. Study sites: 108 to 110v68
  3. Site details revised at 6 of 108 sitesv67
  4. Site details revised at 16 of 108 sitesv66
  5. Site details revised at 9 of 108 sitesv65
Show 45 earlier versionsHide 45 earlier versions
  1. Site details revised at 21 of 108 sitesv64
  2. Site details revised at 57 of 108 sitesv63
  3. Study sites: 105 to 108v62
  4. Study sites: 104 to 105v61
  5. Primary completion date: Nov 2028 to May 2027v60
  6. Study sites: 103 to 104v59
  7. Trial status: Active, Not Recruiting to Recruitingv58 Show 5 more changesShow less
    • Primary completion date: Nov 2027 to Nov 2028
    • Enrollment target: 249 to 366
    • Study completion date: Nov 2028 to Nov 2029
    • Eligibility criteria expanded, about 14 words
    • Site details revised at 103 of 103 sites
  8. Primary completion date: Nov 2025 to Nov 2027
    • Study sites: 97 to 103
    • Study completion date: Nov 2025 to Nov 2028
    v57
  9. Study sites: 95 to 97v56
  10. Study sites: 93 to 95v55
  11. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 93 of 93 sites
    v54
  12. Study sites: 92 to 93v53
  13. Study sites: 86 to 92v52
  14. Study sites: 85 to 86v51
  15. Study sites revised (85)v50
  16. Study sites: 84 to 85v49
  17. Study sites: 83 to 84v48
  18. Site details revised at 2 of 83 sitesv47
  19. Study sites: 82 to 83v46
  20. Study sites: 78 to 82v45
  21. Study sites: 76 to 78v44
  22. Study sites: 75 to 76v43
  23. Study sites: 74 to 75v42
  24. Study sites: 72 to 74v41
  25. Study sites: 71 to 72v40
  26. Study sites: 69 to 71v39
  27. Site details revised at 1 of 69 sitesv38
  28. Site details revised at 2 of 69 sitesv37
  29. Study sites: 66 to 69v36
  30. Study sites: 60 to 66v35
  31. Study sites: 58 to 60v34
  32. Study sites: 54 to 58v33
  33. Study sites: 55 to 54v32
  34. Study sites: 54 to 55
    • Eligibility criteria expanded, about 9 words
    v31
  35. Study sites: 51 to 54v30
  36. Study sites: 48 to 51v29
  37. Study sites: 47 to 48v28
  38. Site details revised at 1 of 47 sitesv27
  39. Site details revised at 5 of 47 sitesv26
  40. Study sites: 45 to 47v25
  41. Study sites: 43 to 45
    • Primary completion date: Aug 2025 to Nov 2025
    • Study completion date: Dec 2025 to Nov 2025
    • Start date: Sep 16, 2022 to Jun 16, 2022
    v24
  42. Site details revised at 3 of 43 sitesv23
  43. Study sites: 39 to 43v22
  44. Study sites: 37 to 39v21
  45. Re-verified, no change to tracked fieldsv20
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Trial Details
NCT Number NCT05429632
Lead Sponsor Priothera SAS
Conditions
(from sponsor)		 Adult Acute Myeloid Leukemia
Related terms Leukemia, Myeloid, Acute
Enrollment 366 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov